Biodexa Pharmaceuticals PLC held a General Meeting where all proposals were approved. The proposals included reducing the nominal value per ordinary share and granting the Directors the authority to allot ordinary shares on a non-pre-emptive basis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003838), on June 11, 2025, and is solely responsible for the information contained therein.